of Biochemistry and Cell Biology, SIBS, CAS. It is published monthly
in printed and electronic versions. Information about ABBS is
available online at: https://www.abbs.info
or http://www.blackwell-synergy.com/loi/abbs.
Its editorial policies are the responsibility of the Editor-in-Chief,
the Associate Editors, and the Editorial Board under the Institute
of Biochemistry and Cell Biology.
ABBS publishes papers based on original research that are judged,
after editorial review, to make a novel and important contribution
to the understanding of any area of biochemistry, biophysics
or molecular biology. Manuscripts may be submitted for consideration
as Regular Papers or Accelerated Publications. ABBS also publishes
Reviews, all of which are by invitation only. Authors are urged
to keep the length of Regular Papers to six printed pages or
less. Accelerated Publications are intended to present new information
of exceptional novelty, importance and interest to the broad
readership of ABBS. Accelerated Publications must be four printed
pages or less, including all figures, references and tables.
They are not intended simply to be short versions of Regular
Papers.
For detailed submission instructions see https://www.abbs.info/instrauthor.htm
It is the responsibility of the Editor-in-Chief, the Associate
Editors, and the Editorial Board to determine the suitability
of a manuscript for publication. After receipt of a manuscript
by the Editor, it is sent to an Associate Editor who usually
assigns it to a member of the Editorial Board. The Board member
then makes a recommendation for acceptance, revision, or declination
based on the scientific merit and technical quality of the studies
reported. Reviewers may be consulted when additional expertise
is required.
All Board members and reviewers who review a manuscript remain
unknown to the authors. Every manuscript is treated by the editors
and reviewers as privileged information, and they are instructed
to exclude themselves from review of any manuscript that might
involve a conflict of interest or the appearance thereof.
The primary criteria for judging the acceptability of a manuscript
are its novelty and scientific importance. Manuscripts judged
lacking in these respects will be declined, even if the experimental
work appears technically sound. This policy permits declination
of a manuscript solely on the Editorial Board’ s judgment that
the studies reported are not sufficiently novel or important
to merit publication in ABBS.
As a condition of publication, all authors must transfer copyright
to the Institute of Biochemistry and Cell Biology. Manuscripts
submitted under multiple authorship are reviewed on the assumption
that all listed authors concur in the submission and that the
final version of the manuscript has been seen and approved by
all authors.
Authors of papers published in ABBS are obligated to honor
any reasonable request by qualified investigators for unique
propagative materials, such as cell lines, hybridomas, DNA clones,
and organisms that are described in the paper. The primary data
obtained from genome- or proteome- scale analyses must be submitted
for review in electronic form. If computer software programs
are developed and used in submitted manuscripts, the programs
must be made available to the reviewer upon request. The source
code or the program must be made available, either commercially
or in downloadable form from the authors, if the manuscript
is accepted for publication. The Editors may deny further publication
rights in ABBS to authors unwilling to abide by these principles.